Tenon Medical (NASDAQ:TNON) Issues Earnings Results

Tenon Medical (NASDAQ:TNON) released its quarterly earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports. Tenon Medical had a negative net margin of 318.36% and a negative return on equity of 409.16%.

Here are the key takeaways from Tenon Medical’s conference call:

• Tenon reported Q1 revenue of $1.4 million, nearly doubling year over year, with gross margin expanding to 68.5% from 44.5% last year. Management said these were the best first-quarter revenue and gross profit results in company history.
• Growth was driven by higher Catamaran procedure volumes and the first full quarter of meaningful SImmetry+ contribution after the SiVantage acquisition. The company said physician training and adoption remained strong, with 21 physicians trained during the quarter.
• The company closed a $4.3 million senior convertible note financing in March, which it said extends runway and supports ongoing investment in commercialization, product launches, and clinical programs. Cash and equivalents ended the quarter at $4.6 million, up from $3.8 million at year-end 2025.
• Management highlighted an expanding intellectual property portfolio, now at 29 U.S. patents and 9 international patents granted with 31 applications pending. It also pointed to multiple notices of allowance expected to convert into additional patents later in 2026.
• Tenon outlined several future growth catalysts, including a full SImmetry+ launch, additional platform enhancements in the second half of 2026, and a new approach to the sacro-pelvic anatomy targeted for alpha in Q4 2026. Management expects these launches, along with continued physician training, to support growth into 2027 and beyond.

Tenon Medical Stock Performance

Shares of NASDAQ TNON traded up $0.02 during trading on Tuesday, reaching $0.81. The company had a trading volume of 222,691 shares, compared to its average volume of 730,445. Tenon Medical has a 52 week low of $0.64 and a 52 week high of $2.48. The stock has a market cap of $9.20 million, a PE ratio of -0.41 and a beta of 1.28. The business’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.93.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tenon Medical in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Tenon Medical

A number of institutional investors have recently modified their holdings of TNON. Jane Street Group LLC bought a new stake in shares of Tenon Medical during the first quarter worth approximately $29,000. Geode Capital Management LLC raised its stake in shares of Tenon Medical by 34.6% during the fourth quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock worth $63,000 after buying an additional 17,137 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in shares of Tenon Medical during the fourth quarter worth approximately $98,000. 22.74% of the stock is owned by institutional investors.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.